Newborn screening for cystic fibrosis; a paradigm for public health genetics policy development : proceedings of a 1997 workshop
Published Date:December 12, 1997
Corporate Authors:National Center for Environmental Health (U.S.) ; National Center for Environmental Health (U.S.), Division of Environmental Hazards and Health Effects. ; National Center for Environmental Health (U.S.), Division of Environmental Health Laboratory Sciences. ; ... More ▼
Keywords:Clinical Laboratory Techniques
Cystic Fibrosis Transmembrane Conductance Regulator
Prevention & Control
Clinical Laboratory Techniques/Standards
Cystic Fibrosis/Prevention & Control
Cystic Fibrosis Transmembrane Conductance Regulator/Genetics
Series:MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 46, no. RR-16
Description:Introduction -- Background -- Workshop objectives and agenda -- Summary of plenary presentations -- Work group summaries and recommendations -- Overall workshop conclusions and recommendations -- Reference.
Cystic fibrosis (CF) is a genetic disease that can be detected in newborn infants (i.e., those aged < or = 1 month) by immunotrypsinogen testing. The sensitivity and specificity of such testing can now be improved as a result of the recent discovery of the Cystic Fibrosis Transmembrane Conductance Regulatory (CFTR) gene. Although limited CF screening for newborns has been used since the 1980s, the clinical, social, and economic outcomes of population-based screening are controversial. During January 1997, a workshop was convened at CDC in Atlanta, Georgia to discuss the benefits and risks associated with screening newborns for CF and to develop public health policy concerning such screening. The workshop planning committee comprised representatives from CDC, the Cystic Fibrosis Foundation, the National Institutes of Health, and the University of Wisconsin. Experts in the fields of CF, public health, the screening of newborns, and economics also contributed to discussions. Workshop participants addressed a) benefits and risks, b) laboratory testing, and c) economics concerning the implementation of routine CF screening for newborns. Summaries of these discussions and the resulting workshop recommendations are presented in this report. These recommendations, developed by workshop participants, will be useful to medical and public health professionals and state policymakers who are evaluating the merits of population-based screening of newborns for CF.
Includes bibliographical references (22-24).
Supporting Files:No Additional Files
You May Also Like: